Abstract:Background: Numerous studies have shown that glucose-6-phosphate dehydrogenase (G6PD) is a tumor-promoting factor in a variety of malignancies. However, it is not entirely clear the role and the potential molecular mechanism of G6PDH in the pathogenesis or clinical prognosis of different tumors. Methods: This study first investigated the pan-tumoral expression of G6PD, then G6PD gene expression were studied in cancers, survival prognosis, tumor immunity, immunosuppressive cell infiltration, DNA methylation, gene alteration assay, and response to immunotherapy. We also investigated the function of G6PD in the development and prognosis of various cancers. Results: Our results suggest that G6PD expression was higher in tumor tissues than in normal tissues and was related to tumor stage, metastasis, and prognosis in most cancers and subtypes of the Cancer Genome Atlas. High G6PD expression is protective in a small number of cancers, including paraganglioma, pheochromocytoma, and ovarian serous cystadenocarcinoma. However, it is a risk factor for the majority of cancers. The prognosis for progression-free survival was better in people with G6PD alterations than in those without them. G6PD and immune cell infiltration were significantly positively correlated in prostate cancer, pancreatic adenocarcinoma, liver cancer, and low-grade glioma of the brain. Additionally, the degree of G6PD methylation was shown to inversely correlate with mRNA expression. The PGD, GCLM, SRXN1, TRIM16L, and TXNRD1 genes all showed significant positive correlation with G6PD expression level. The major genetic alterations were missense mutations in G6PD, and mutations at the R192C/S locus were detected in cutaneous melanoma, uterine cancer, and thyroid carcinoma. In several malignancies, G6PD expression is associated with immunological and chemotherapeutic outcomes. Conclusions: According to the study, patients who expressed more G6PD generally had better therapeutic outcomes. Our study highlights the role of G6PD in oncogenesis, detection, prognosis, and treatment planning.

The P52-Zer6/g6pd Axis Alters Aerobic Glycolysis and Promotes Tumor Progression by Activating the Pentose Phosphate Pathway.

JMJD5 Inhibits Lung Cancer Progression by Regulating Glucose Metabolism Through the P53/tigar Pathway

O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth

Zinc-finger Protein P52-Zer6 Accelerates Colorectal Cancer Cell Proliferation and Tumour Progression Through Promoting P53 Ubiquitination.

P53 Regulates Biosynthesis Through Direct Inactivation of Glucose-6-phosphate Dehydrogenase

Transcription factor YY1 promotes cell proliferation by directly activating the pentose phosphate pathway.

PBX3 Promotes Pentose Phosphate Pathway and Colorectal Cancer Progression by Enhancing G6PD Expression.

Tumor Suppressor P53 Cooperates with SIRT6 to Regulate Gluconeogenesis by Promoting FoxO1 Nuclear Exclusion.

Glucose-6-phosphate Dehydrogenase (G6PD): the Role in Tumor Progression and Immunotherapy

p52-ZER6/IGF1R axis maintains cancer stem cell population to promote cancer progression by enhancing pro-survival mitophagy

Pan-cancer analysis of G6PD carcinogenesis in human tumors.

The Fundamental Role of the P53 Pathway in Tumor Metabolism and Its Implication in Tumor Therapy

The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy.

The Emerging Roles of the Metabolic Regulator G6PD in Human Cancers

H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth

G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes

P52-Zer6: a Determinant of Tumor Cell Sensitivity to MDM2-p53 Binding Inhibitors

NeuroD1 promotes tumor cell proliferation and tumorigenesis by directly activating the pentose phosphate pathway in colorectal carcinoma

KRAB-type Zinc-Finger Proteins PITA and PISA Specifically Regulate P53-Dependent Glycolysis and Mitochondrial Respiration

c-Src facilitates tumorigenesis by phosphorylating and activating G6PD

Tumor Suppressor P53 Negatively Regulates Glycolysis Stimulated by Hypoxia Through Its Target RRAD